Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid.

@article{Blackwell2000UsingAT,
  title={Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid.},
  author={Jacqueline L. Blackwell and Hong-li Li and Jes{\'u}s G{\'o}mez-Navarro and Igor S. Dmitriev and Victor N. Krasnykh and Catherine A. Richter and Denise R. Shaw and R R Douglas Alvarez and David T Curiel and Theresa V. Strong},
  journal={Human gene therapy},
  year={2000},
  volume={11 12},
  pages={
          1657-69
        }
}
Peritoneal compartmentalization of advanced stage ovarian cancer provides a rational scenario for gene therapy strategies. Several groups are exploring intraperitoneal administration of adenoviral (Ad) vectors for this purpose. We examined in vitro gene transfer in the presence of ascites fluid from ovarian cancer patients and observed significant inhibition of Ad-mediated gene transfer. The inhibitory activity was not identified as either complement or cellular factors, but depletion of IgG… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 34 CITATIONS

Gene therapy for ovarian cancer

VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

Similar Papers